Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

被引：13

作者：

Locke, Frederick Lundry

Ghobadi, Armin

Lekakis, Lazaros J.

Miklos, David Bernard

Jacobson, Caron A.

Jacobsen, Eric D.

Braunschweig, Ira

Oluwole, Olalekan O.

Siddiqi, Tanya

Lin, Yi

Reagan, Patrick Michael

Farooq, Umar

Deol, Abhinav

Bot, Adrian

Rossi, John M.

Jiang, Yizhou

Xue, Allen

Go, William Y.

Neelapu, Sattva Swarup

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3039

引用

页数：2

共 50 条

[31] Interim Analysis of ZUMA-5: a Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Jacobson, Caron
Chavez, Julio
Sehgal, Alison
William, Basem
Munoz, Javier
Salles, Gilles
Casulo, Carla
Munshi, Pashna
Maloney, David
de Vos, Sven
Reshef, Ran
Leslie, Lori
Yakoub-Agha, Ibrahim
Oluwole, Olalekan
Fung, Henry Chi Hang
Plaks, Vicki
Yang, Yin
Lee, Jennifer
Avanzi, Mauro
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S20 - S21
[32] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Topp, Max
Van Meerten, Tom
Houot, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duhrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose'
BLOOD, 2019, 134
[33] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
Locke, F. L.
Neelapu, S. S.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J.
Elias, M.
Wiezorek, J.
Go, W. Y.
HAEMATOLOGICA, 2017, 102 : 172 - 172
[35] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
Sun, Jennifer
BLOOD, 2018, 132
[36] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Sun, Jennifer
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[37] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Hout, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin W.
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rong
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
[38] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
Schmitz, N.
Oluwole, O. O.
Bishop, M. R.
Gisselbrecht, C.
Gordon, L. I.
Kersten, M. J.
Maloney, D. G.
Caballero, M. D.
Kuruvilla, J.
Song, K. W.
Jacobson, C. A.
Nastoupil, L. J.
Riedell, P.
Jiang, Y.
Rossi, J. M.
Lee, L.
Cheng, P.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
[39] Axicabtagene Ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory diffuse large B cell lymphoma: The phase 3, randomized study, ZUMA-7
Schmitz, N.
Oluwole, O. O.
Bishop, M. R.
Gisselbrecht, C.
Gordon, L. I.
Kersten, M. J.
Maloney, D. G.
Caballero, M. D.
Kuruvilla, J.
Song, K. W.
Jacobson, C. A.
Nastoupil, L. J.
Riedell, P.
Jiang, Y.
Rossi, J. M.
Lee, L.
Cheng, P.
Locke, F. L.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 47 - 47
[40] Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
Oluwole, Olalekan O.
Bishop, Michael R.
Gisselbrecht, Christian
Gordon, Leo I.
Kersten, Marie Jose
Maloney, David G.
Schmitz, Norbert
Dolores Caballero, Maria
Kuruvilla, John
Song, Kevin W.
Jacobson, Caron A.
Nastoupil, Loretta J.
Riedell, Peter
Jiang, Yizhou
Rossi, John M.
Lee, Lillian
Cheng, Paul
Locke, Frederick L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S293 - S294

← 1 2 3 4 5 →